Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Alector, Inc. reported collaboration revenue of $162.9 million and net income of $124.6 million for the three months ended September 30, 2026, versus $3.3 million in revenue and a $34.7 million net loss a year earlier. Revenue included recognition of $162.9 million in GSK deferred revenue after Alector concluded no performance obligations remained; it expects no further GSK revenue and continued net losses.
On September 30, 2026, Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050. It received a $100.0 million upfront payment after quarter-end and may receive up to $1.17 billion in milestones plus tiered royalties. Alector paid Spur $15.0 million on November 2 under its GCase license; an October offering closed October 19, issuing 36.6 million shares at $2.05 for approximately $75.0 million gross before expenses.
Cash, cash equivalents and marketable securities were $138.7 million as of September 30, 2026; operating activities used $108.2 million in the first nine months. Based on its current operating plan, Alector anticipates funding operations into the second half of 2029 using its existing balances, the subsequent license payment net of the Spur payment, and October offering net proceeds. Latozinemab and nivisnebart were discontinued after trial results; AL137 first-in-human dosing in Australia is targeted by April 2027.
Alector, Inc. reported third-quarter 2026 collaboration revenue of $162.9 million, versus $3.3 million a year earlier, and net income of $124.6 million, versus a $34.7 million net loss. The revenue increase primarily reflected recognition of remaining deferred revenue under its GSK collaboration after GSK’s termination notice and the extinguishment of remaining performance obligations.
Alector granted Genentech exclusive global rights to develop and commercialize AL050; Alector received a $100 million upfront payment and is eligible for up to an additional $1.17 billion in milestone payments plus tiered royalties. Alector completed an underwritten offering of 36,600,000 shares at $2.05 each for approximately $75.0 million in gross proceeds. Cash, cash equivalents and investments were $138.7 million as of September 30, 2026, before the later Genentech payment, the $15.0 million option exercise payment to Spur Therapeutics on November 2, 2026, and offering proceeds. Management expects the cash balance, Genentech payment and net offering proceeds to fund operations into the second half of 2029. AL137 targets first-in-human dosing in Australia no later than April 2027; AL164 and AL062 target first-in-human studies in Q2 2028.
Alector, Inc. (ALEC) ownership disclosure lists RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah and RA Capital Healthcare Fund, L.P. as reporting persons; each reports beneficial ownership of 7,500,000 shares, or 5.1%. The Fund directly holds the shares and delegated the sole power to vote and dispose of them to RA Capital, its investment adviser.
The Fund states it has divested voting and investment power and disclaims beneficial ownership for Section 13(d) purposes. RA Capital, Kolchinsky and Shah also disclaim beneficial ownership except for determining their Section 13(d) obligations. The 5.1% calculation uses 111,656,919 shares outstanding as of July 31, 2026, and 36,600,000 shares issued in the public offering that closed October 19, 2026.
Alector, Inc. common stock was reported as beneficially owned by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. Each reporting person reported 12,772,152 shares, or 8.61%, as of October 23, 2026. They reported shared voting and dispositive power over those shares, with no sole voting or dispositive power. The percentage calculation uses 148,256,805 shares outstanding as of October 16, 2026.
Alector, Inc. (ALEC) is offering 36,600,000 shares of common stock at $2.05 per share, an aggregate offering price of $75,030,000. The underwriters will purchase the shares from Alector at $1.927 per share, representing $70,528,200 to the company before offering expenses; estimated net proceeds are approximately $70.2 million. Delivery is expected on or about October 19, 2026.
Alector intends to use net proceeds for general corporate purposes, including research, development and manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and acquisitions or strategic transactions. Pending use, it intends to invest the proceeds in short-term, investment-grade, interest-bearing instruments; management retains broad discretion over timing and application. Shares outstanding were 111,656,805 as of June 30, 2026. The prospectus estimates immediate dilution to new investors of $1.64 per share in net tangible book value.
Alector and its directors and executive officers agreed to restrictions on sales and other transfers of common stock during the 30-day restricted period, subject to underwriter consent and specified exceptions. The company also agreed not to sell shares under its separate sales agreement until that period expires or is waived.
Alector, Inc. (ALEC) priced an underwritten offering of 36,600,000 common shares at $2.05 per share; Alector is selling all of the shares. Gross proceeds are expected to be $75,030,000.00 before underwriting discounts and commissions and other offering expenses payable by the company. The offer price represents an approximately 7.3% premium over the October 15, 2026 closing price.
The offering is expected to close October 19, 2026, subject to customary closing conditions. Alector anticipates using net proceeds for general corporate purposes, which may include research, development and manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and acquisitions or strategic transactions involving complementary products, technologies or businesses. TCGX, BVF Partners, ADAR1 Capital Management and Deep Track Capital are among participating new and existing investors. Morgan Stanley & Co. LLC and BTIG, LLC are joint lead book-running managers. The offering is under Alector’s effective Form S-3 registration statement.
Alector, Inc. (ALEC) Chief Executive Officer Arnon Rosenthal reported a grant of 217,500 restricted stock units on October 14, 2026, bringing his reported direct common-stock holdings to 2,512,100 shares. The RSUs vest in 12 equal quarterly installments beginning December 1, 2026. He also reported 978,750 options granted at an exercise price of $1.88 per share, vesting in 48 equal monthly installments beginning November 13, 2026.
A one-time repricing effective October 13, 2026 applied to options with exercise prices above $1.87 held by continuing employees; the reported repriced options were amended to an exercise price of $1.87 per share. Exercising a repriced eligible option before the Retention Period ends requires a premium equal to its original exercise price.
Alector, Inc. (ALEC) reported equity awards to Principal Accounting Officer Grace Wong-Sarad on October 14, 2026: 55,555 restricted stock units (RSUs) and options covering 83,435 shares, with a $1.88 exercise price. The RSUs vest in 12 equal quarterly installments beginning December 1, 2026; the options vest in 48 equal monthly installments beginning November 13, 2026. Direct common-stock holdings after the RSU award were 161,570 shares.
Alector’s Option Repricing was effective October 13, 2026. Existing options covering six disclosed share lots were disposed of to the issuer, and replacement options for the corresponding share counts were granted at a $1.87 exercise price. If an employee exercises a repriced option before the Retention Period ends, the premium exercise price equals the option’s original exercise price. The period ends at the earliest of one year following the Effective Date, a Change in Control, or the employee’s death or Disability.
Alector, Inc. (ALEC) CFO & Chief Business Officer Neil Lindsay Berkley received awards on October 14, 2026, consisting of 44,567 restricted stock units and options covering 190,000 common shares. The RSUs vest in 12 equal quarterly installments beginning December 1, 2026; his reported direct common-stock position following the RSU award was 395,216 shares. The options have a $1.88 exercise price, vest in 48 equal monthly installments beginning November 13, 2026, and expire October 13, 2036.
Alector, Inc. approved an option repricing effective October 13, 2026, setting the exercise price for eligible options at $1.87 per share. It generally covered options granted to current employees under the 2019 Equity Incentive Plan or 2017 Stock Option and Grant Plan, held by continuing employees and priced above $1.87. Approximately 4.05 million shares underlie all repriced options. These include options for 2,421,197 shares held by Arnon Rosenthal, Ph.D., Co-founder and Chief Executive Officer (original exercise prices of $6.48–$23.70), and 87,385 shares held by Grace Wong-Sarad, Chief Accounting Officer and principal accounting officer (original exercise prices of $9.46–$23.70).
An employee exercising a repriced option before the Retention Period ends must pay its original exercise price. The period ends at the earliest of one year after the effective date, a Change in Control, or the option holder’s death or Disability. The repricing does not change option expiration dates, service-based vesting criteria, or the number of underlying shares.